EU Medicines Regulation Achievements: EMA’...

By HEOR Staff Writer

March 16, 2026

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Accelerating FAST-EU Clinical Trials
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Navigating Economic Resilience Through Life Sciences Investment